Krystal Biotech Reports Strong U.S. Performance as International Launch Navigates Reimbursement Hurdles
The gene therapy company posted $91.6 million in U.S. revenue for Q2 2026 while expanding its pipeline and working through pricing negotiations across Europe.
U.S. Business Drives Growth
Krystal Biotech reported U.S. net revenue of $91.6 million for the second quarter of 2026, demonstrating continued commercial momentum for VYJUVEK, its gene therapy for dystrophic epidermolysis bullosa (DEB). The company has secured more than 730 U.S. reimbursement approvals, surpassing its initial penetration target of 60% of the diagnosed DEB patient population (earnings call, 2026-08-03).
Christine Wilson, Senior Vice President and Head of U.S. Commercial, attributed the performance to the field team's expanding reach into community settings and strengthening patient engagement programs. The company has launched initiatives including VYJUVEK Voices and VYJUVEK Connections to support patients as they incorporate the therapy into long-term wound care routines (earnings call, 2026-08-03).
International Revenue Flat Amid Reimbursement Work
Reported revenue in Europe and Japan remained "broadly flat" during the quarter, primarily due to a reserve provision related to ongoing pricing negotiations in Germany, according to Laurent Goux, Executive Vice President and General Manager for Europe (earnings call, 2026-08-03). Despite the revenue headwind, management emphasized that underlying demand remains strong across international markets.
The company is advancing pricing and reimbursement discussions in Germany, France, Italy, Spain, and the United Kingdom. Germany, Italy, and Spain are expected to reach key pricing outcomes before year-end 2026, while formal discussions in France are anticipated to extend into 2027 (earnings call, 2026-08-03).
In the U.K., VYJUVEK received marketing authorization from the MHRA in May, becoming "the first genetic medicine approved in the U.K. for DEB," and subsequently received the 2026 U.K. award for best product for orphan disease in June (earnings call, 2026-08-03). Additional regulatory submissions are planned for Switzerland and Australia in coming months.
Pipeline Advances Toward Multiple Readouts
Krystal's clinical pipeline is progressing across several fronts, with two registrational studies currently underway. The ELITE study evaluating KB803 in DEB patients completed enrollment in April and remains on track for a readout later this year. Success would enable rapid BLA submission leveraging existing CMC work from VYJUVEK (earnings call, 2026-08-03).
The registrational study for KB801 in neurotrophic keratitis (NK) patients is expected to complete enrollment before year-end, with results anticipated shortly after given the eight-week primary endpoint (earnings call, 2026-08-03).
Suma Krishnan, President of Research and Development, highlighted progress in repeat-dose studies for KB407 in cystic fibrosis and KB11, both of which "have the potential to advance into registrational development in 2027" assuming supportive data (earnings call, 2026-08-03). The company is also advancing its KB707 oncology program, with an inhaled formulation for NSCLC on track for a registrational study next year.
Financial Position
CEO Krish Krishnan emphasized that the company remains "in a very strong financial position," reflecting both commercial business growth and operational discipline maintained over the past 12 quarters. This financial strength enables continued investment in global expansion and pipeline development (earnings call, 2026-08-03).
With a market capitalization near $10 billion and shares closing at $341.12, Krystal Biotech continues to balance commercial execution in its core DEB franchise with expansion into multiple therapeutic areas through its HSV-1 vector platform.
This article was generated by MarginX from the earnings call on 2026-08-03. It is not investment advice.